Clinical trials: Germ Cell Neoplasm
Melanoma
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma
This is a monocentric prospective study. This study aims to investigate the prognostic value of the novel melanin-targeted imaging modality 18F-PFPN PET in patients with melanoma and seek independent prognostic factors for…
- Trial name
- NCT05645484
- Testing
- 18F-PFPN, 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma.
- Trial name
- NCT07452458
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 54 sites in United States
- Volunteers
- 398 people
- Sponsor
- NRG Oncology
Glioblastoma, Glioblastoma (GBM)
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when administered twice into the brain where the tumor is located. This is a Phase IB 2 dosing study.
- Conditions
- Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III
- Trial name
- NCT06614855
- Testing
- C134
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- James Markert, MD
Advanced Solid Tumor
A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.
- Trial name
- NCT06936735
- Testing
- HS-20108 Monotherapy
- Where
- China
- Volunteers
- 502 people
- Sponsor
- Hansoh BioMedical R&D Company
Melanoma, Cancer
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Primary objective: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.
- Trial name
- NCT00613509
- Testing
- ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha -2b
- Where
- 19 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how…
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT00674193
- Testing
- pharmacological study, laboratory biomarker analysis
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Glioblastoma Multiforme
Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients
Currently, the optimal treatment regimen for elderly Glioblastoma (GBM) patients with poor performance status (PS) is unknown. Based on data for elderly GBM patients and the limited data for patients with poor PS…
- Trial name
- NCT04765514
- Testing
- Temozolomide monotherapy, Chemo-Radiotherapy with concurrent temozolomide.
- Where
- 2 sites in Canada
- Volunteers
- 107 people
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma, Gliosarcoma
Sorafenib in Newly Diagnosed High Grade Glioma
This is a phase I study to evaluate the safety and tolerability of Sorafenib in combination with Temodar and radiation therapy in patients with newly diagnosed high grade glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
- Trial name
- NCT00884416
- Testing
- Sorafenib dose escalation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- University Hospital, Geneva
Solid Tumor
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors.
- Trial name
- NCT05798533
- Testing
- Neo-T, Toripalimab, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- BGI, China
Brain Tumor, Recurring Glioblastoma
Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma
In the Netherlands a 2 center investigator-driven phase I/II clinical trial is initiated in June 2010 testing the oncolytic adenovirus Delta24-RGD to treat glioblastoma patients.
- Trial name
- NCT01582516
- Testing
- delta-24-RGD adenovirus
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Neurofibromatosis 2, Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma
- Trial name
- SEL-TH-1601 (NCT03095248)
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Melanoma, Non-melanoma Skin Cancer
DERM Health Economics Study
This study aims to provide an initial assessment of the potential impact DERM could have on the number of onward referrals for a face to face dermatologist review and/or biopsy from a teledermatology-based service, and to improve…
- Trial name
- NCT04123678
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- Skin Analytics Limited
Cutaneous Tumor, Optical Coherence Tomography
Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)
This project aims to validate ex vivo the use of the OCTAV® prototype integrating the "dermoscope" function before an in vivo application, by comparing images obtained by the OCTAV® prototype integrating the "dermoscope" function…
- Conditions
- Cutaneous Tumor, Optical Coherence Tomography, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- DERMOCTAV (NCT05340543)
- Testing
- Confocal optical coherence tomography - OCTAVE
- Where
- France
- Volunteers
- 150 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma
RATIONALE: Glutamine may help prevent mucositis, or mouth sores, in patients receiving chemotherapy for sarcoma. It is not yet known whether glutamine is more effective than a placebo in preventing mucositis in patients receiving…
- Trial name
- NCT00334984
- Testing
- glutamine, chemoprotection, management of therapy complications
- Sponsor
- Children's Oncology Group
Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma
Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
The primary aim of this study is to determine the presence of gemcitabine in childhood diffuse midline gliomas (DMG) (previously classified as diffuse intrinsic pontine glioma [DIPG]) after systemic treatment with the drug.
- Conditions
- Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma, Glioma
- Trial name
- NCT04051047
- Testing
- Gemcitabine, Tumor biopsy and blood draw
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System
S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00017147
- Testing
- carmustine, radiation therapy, O6-Benzylguanine
- Where
- 163 sites in United States
- Volunteers
- 183 people
- Sponsor
- SWOG Cancer Research Network
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Astrocytoma, Glioblastoma
Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
Glioblastomas, the most frequent malignant brain tumor in adults, are widespread in the brain, despite their discrete appearance on computed tomography (CT) or magnetic resonance imaging (MRI).
- Conditions
- Astrocytoma, Glioblastoma, Glioma
- Trial name
- NCT00001148
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
Neuroendocrine Tumors, Liver Metastases
A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
By improved kidney dosimetry including biological effective dose and taking into account potential risk factors (especially for kidney toxicity), it might be possible to give an optimal and personalized treatment with…
- Trial name
- ILUMINET (NCT01456078)
- Testing
- 177Lu-DOTA-TATE
- Where
- 2 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Lund University Hospital